Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 18, 2003. The report details specific corporate actions regarding share buybacks and changes in directors' interests, rather than providing comprehensive financial results for a fiscal quarter or year.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific share repurchase transactions:
- September 16, 2003: Purchased 781,000 ordinary shares at 1,280.21p per share.
- September 17, 2003: Purchased 770,000 ordinary shares at 1,294.39p per share.
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,551,000 ordinary shares purchased on September 16 and 17, 2003. These transactions were executed under authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Management Commentary and Corporate Actions
Management executed the share buybacks in accordance with shareholder authorization. Additionally, the filing reports a change in directors' interests involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On September 16, 2003, the Trust transferred 9,641 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the GSK Trust as potential beneficiaries alongside other employees.
Investor Verification Checklist
- Verify the total number of shares repurchased and cancelled during the reporting period (1,551,000 shares).
- Confirm the average price paid per share during the buyback window (approx. 1,287p).
- Review the remaining buyback authority available under the May 19, 2003 shareholder resolution.
- Check subsequent filings for the impact of these cancellations on earnings per share (EPS) and total share count.